Article Detail - JE Part A
National Coverage Determination (NCD 90.3): CAR T-cell Therapy
MLN Matters Number: MM11783
Related CR Release Date: November 13, 2020
Related CR Transmittal Number: R10454CP and R10454NCD
Related Change Request (CR) Number: 11783
Effective Date: August 7, 2019
Implementation Date: February 16, 2021
CR 11783 informs you that effective for claims with dates of service on or after August 7, 2019, the Centers for Medicare & Medicaid Services (CMS) covers autologous treatment for cancer with T-cells expressing at least one Chimeric Antigen Receptor (CAR) when administered at healthcare facilities enrolled in the Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategies (REMS) and meets specified FDA conditions.
Make sure your billing staffs are aware of these changes.
View the complete CMS Medicare Learning Network (MLN) Matters (MM)11783.
Last Updated Thu, 19 Nov 2020 22:20:39 +0000